Related references
Note: Only part of the references are listed.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases
B. Pariente et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people
J. F. Mayberry et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy
T. Molnar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben-Horin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Inflammatory bowel disease epidemiology
Johan Burisch et al.
CURRENT OPINION IN GASTROENTEROLOGY (2013)
A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn's Disease
Derek H. Tang et al.
INFLAMMATORY BOWEL DISEASES (2013)
Mucosal Healing in Inflammatory Bowel Disease
Mark T. Osterman
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: A cost-effectiveness analysis
Shota Saito et al.
JOURNAL OF CROHNS & COLITIS (2013)
When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel
Valerie Pittet et al.
JOURNAL OF CROHNS & COLITIS (2013)
Histological healing in inflammatory bowel disease: A still unfulfilled promise
Vincenzo Villanacci et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry
Fabiola Atzeni et al.
AUTOIMMUNITY REVIEWS (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Mucosal healing in inflammatory bowel diseases: a systematic review
Markus F. Neurath et al.
GUT (2012)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn's Disease Treated With Combination Therapy
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
Harry Sokol et al.
GUT (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2010)
Value of mucosal assessment and biomarkers in inflammatory bowel disease
Ryan W. Stidham et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle
H. Sokol et al.
GUT (2009)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
M. Henriksen et al.
GUT (2008)
Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
Kathrine Frey Froslie et al.
GASTROENTEROLOGY (2007)
A simple biological score for predicting low risk of short-term relapse in Crohn's disease
Yann Consigny et al.
INFLAMMATORY BOWEL DISEASES (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Oratory markers in IBD: Magic, or unneccessary toys?
S Vermeire et al.
GUT (2006)
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease
CA Solem et al.
INFLAMMATORY BOWEL DISEASES (2005)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
C-reactive protein as a marker for inflammatory bowel disease
S Vermeire et al.
INFLAMMATORY BOWEL DISEASES (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
